{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:46:30Z","timestamp":1793195190283,"version":"4.5.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1097\/inf.0000000000001518","type":"journal-article","created":{"date-parts":[[2016,12,29]],"date-time":"2016-12-29T19:55:10Z","timestamp":1483041310000},"page":"e136-e150","source":"Crossref","is-referenced-by-count":5,"title":["Immunogenicity and Safety of 10-valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Administered to Children With Sickle Cell Disease Between 8 Weeks and 2 Years of Age"],"prefix":"10.1097","volume":"36","author":[{"given":"Sodiomon B.","family":"Sirima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Tiono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zakaria","family":"Gansan\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamadou","family":"Siribi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang\u00e8le","family":"Zongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alphonse","family":"Ou\u00e9draogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Fran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Strezova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Dobbelaere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Borys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-17-20210202","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/pbc.22461","article-title":"Susceptibility to invasive bacterial infections in children with sickle cell disease.","volume":"55","author":"Battersby","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"R2-17-20210202","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1056\/NEJM198606193142501","article-title":"Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial.","volume":"314","author":"Gaston","year":"1986","journal-title":"N Engl J Med"},{"key":"R3-17-20210202","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1067\/S0022-3476(03)00331-7","article-title":"Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination.","volume":"143","author":"Adamkiewicz","year":"2003","journal-title":"J Pediatr"},{"key":"R4-17-20210202","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1086\/516781","article-title":"Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine.","volume":"44","author":"Halasa","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R6-17-20210202","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/INF.0b013e31814614c6","article-title":"Immunogenicity and safety of a pneumococcal conjugate 7-valent vaccine in infants with sickle cell disease.","volume":"26","author":"Reinert","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"R7-17-20210202","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1542\/peds.106.5.965","article-title":"Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM(197) among infants with sickle cell disease. Pneumococcal Conjugate Vaccine Study Group.","volume":"106","author":"O\u2019Brien","year":"2000","journal-title":"Pediatrics"},{"key":"R8-17-20210202","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1542\/peds.2007-0018","article-title":"Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life.","volume":"121","author":"Adamkiewicz","year":"2008","journal-title":"Pediatrics"},{"key":"R9-17-20210202","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/pbc.25502","article-title":"13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.","volume":"62","author":"De Montalembert","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"R10-17-20210202","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1128\/CVI.00289-09","article-title":"Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines.","volume":"17","author":"Poolman","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"R11-17-20210202","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1097\/INF.0b013e3182323ac2","article-title":"Induction of immunologic memory following primary vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in infants.","volume":"31","author":"Knuf","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"R12-17-20210202","doi-asserted-by":"crossref","first-page":"382","DOI":"10.4161\/hv.22692","article-title":"Safety, reactogenicity and immunogenicity of a booster dose of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children.","volume":"9","author":"Dicko","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"R13-17-20210202","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/INF.0b013e3181f2da06","article-title":"Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with DTPw-HBV\/Hib and poliovirus vaccines.","volume":"30","author":"Bermal","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R14-17-20210202","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1097\/INF.0b013e31822a8541","article-title":"Response to primary and booster vaccination with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in Korean infants.","volume":"30","author":"Kim","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R15-17-20210202","doi-asserted-by":"crossref","first-page":"511","DOI":"10.4161\/hv.7.5.14634","article-title":"Safety and immunogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Chilean children.","volume":"7","author":"Lagos","year":"2011","journal-title":"Hum Vaccin"},{"key":"R16-17-20210202","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1097\/INF.0b013e3181b48ca3","article-title":"Immunogenicity of a 2-dose priming and booster vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine.","volume":"28","author":"Silfverdal","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"R17-17-20210202","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1097\/INF.0b013e3181dffabf","article-title":"Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months.","volume":"29","author":"Vesikari","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"R18-17-20210202","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1097\/INF.0b013e318199f609","article-title":"Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.","volume":"28","author":"Wysocki","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"R19-17-20210202","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1097\/INF.0b013e318199f901","article-title":"The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV\/Hib and poliovirus vaccines: assessment of immunogenicity.","volume":"28","author":"Bermal","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"R20-17-20210202","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1097\/INF.0b013e318199f8ef","article-title":"Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.","volume":"28","author":"Vesikari","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"R21-17-20210202","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1097\/INF.0b013e318199f61b","article-title":"Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).","volume":"28","author":"Knuf","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"R22-17-20210202","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1186\/1471-2458-11-882","article-title":"Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial.","volume":"11","author":"Dicko","year":"2011","journal-title":"BMC Public Health"},{"key":"R23-17-20210202","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1128\/CDLI.7.5.788-793.2000","article-title":"Serum opsonic activity in infants with sickle-cell disease immunized with pneumococcal polysaccharide protein conjugate vaccine. The Pneumococcal Conjugate Vaccine Study Group.","volume":"7","author":"Nowak-Wegrzyn","year":"2000","journal-title":"Clin Diagn Lab Immunol"},{"key":"R24-17-20210202","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1016\/j.vaccine.2015.04.005","article-title":"Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada.","volume":"33","author":"Deceuninck","year":"2015","journal-title":"Vaccine"},{"key":"R25-17-20210202","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-2600(14)70060-8","article-title":"Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study.","volume":"2","author":"Domingues","year":"2014","journal-title":"Lancet Respir Med"},{"key":"R26-17-20210202","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0140-6736(12)61854-6","article-title":"Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial.","volume":"381","author":"Palmu","year":"2013","journal-title":"Lancet"},{"key":"R27-17-20210202","doi-asserted-by":"crossref","first-page":"e1001657","DOI":"10.1371\/journal.pmed.1001657","article-title":"Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind randomized controlled trial.","volume":"11","author":"Tregnaghi","year":"2014","journal-title":"PLoS Med"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000001518","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:13:54Z","timestamp":1620954834000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201705000-00017"}},"subtitle":["A Phase III, Open, Controlled Study"],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001518","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]}}}